Physicochemical Properties
| Molecular Formula | C12H11N5OS2 |
| Molecular Weight | 305.38 |
| CAS # | 1799330-91-8 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | COX-2 |
| ln Vitro | LFS-1107 (4–9 μM, 72 h) has an excellent safety profile in PBMC cell lines and preferentially kills ENKT L cells while leaving healthy human PBMC intact [1]. On human platelets, LFS-1107 (0.15-500 μM, 24 h) shows minimal effect [1]. In 293T cells, LFS-1107 (50-200 nM, 3 h) can accumulate IκBα[1]. |
| ln Vivo | In a mouse model xenografted with SNK6 cells, LFS-1107 (10 mg/kg, intraperitoneal injection, once a week) can alleviate ENKTL symptoms[1]. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: SNK6, HANK-1 Tested Concentrations: 0-800 nM Incubation Duration: 72 h Experimental Results: Achieved IC50 value of 26 nM in SNK6 cell line and 36 nM in HANK-1 cell line. Western Blot Analysis [1] Cell Types: SNK6 Tested Concentrations: 62.5 nM, 125 nM, 250 nM, 500 nM, 1000 nM Incubation Duration: 3 h Experimental Results: Suppressed the expression of CRM1 in a dose-dependent manner. Downregulated the expression of proinflammatory and proliferative proteins p65, COX-2, c-Myc, and Survivin in a dose dependent manner. Immunofluorescence[1] Cell Types: 293T cells Tested Concentrations: 50 nM, 100 nM, 200 nM Incubation Duration: 3 h Experimental Results: Could lead to nuclear accumulation of IκBα in a dose dependent manner. |
| Animal Protocol |
Animal/Disease Models: SNK6 cell xenograft mouse model[1] Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection (ip), once a week Experimental Results: Extended mouse survival and Eliminated tumor cells. |
| References |
[1]. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma eLife 12:e80625. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2746 mL | 16.3730 mL | 32.7461 mL | |
| 5 mM | 0.6549 mL | 3.2746 mL | 6.5492 mL | |
| 10 mM | 0.3275 mL | 1.6373 mL | 3.2746 mL |